Efficacy and safety of Herceptin in women with Her2-positive (HER2+) metastatic breast cancer (MBC) who have progressed on a prior herceptin-containing regimen.

被引：0
|
作者：
Gelmon, K [1 ]
Mackey, J [1 ]
Verma, S [1 ]
Gertler, SZ [1 ]
Bangermann, N [1 ]
Klimo, P [1 ]
Schneeweiss, A [1 ]
Bremer, K [1 ]
Soulieres, D [1 ]
Tonkin, K [1 ]
Bell, R [1 ]
Heinrich, B [1 ]
机构：
[1] BC Canc Agcy, Vancouver, BC, Canada
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2002年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
440
引用
收藏
页码：S113 / S113
页数：1
相关论文
共 50 条
  • [1] Trastuzumab (herceptin) and HER2-positive breast cancer
    Murray, S
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2006, 174 (01) : 36 - 37
  • [2] Her2-positive breast cancer: Herceptin and beyond
    Dean-Colomb, Windy
    Esteva, Francisco J.
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (18) : 2806 - 2812
  • [3] HER2-positive (HER2+) metastatic breast cancer (MBC) presentation and patterns of progression
    Di Cosimo, Serena
    Serpico, Danila
    Porcu, Luca
    Tessari, Anna
    Molino, Leonardo
    Torri, Valter
    de Braud, Filippo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Herceptin in metastatic HER2-positive gastric cancer - GEJ approved
    Jelitto, H. -U.
    VISZERALMEDIZIN, 2010, 26 (02): : 141 - 141
  • [5] A phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer (MBC) who have received prior HER2 regimens for MBC
    Lathrop, K.
    Lucas, J.
    Vacirca, J. L.
    Bhat, G.
    Choi, M. R.
    Naughton, M.
    CANCER RESEARCH, 2017, 77
  • [6] PTEN key to herceptin response in Her2-positive breast cancer
    不详
    CANCER BIOLOGY & THERAPY, 2004, 3 (09) : 796 - 796
  • [7] Clinical predictors of long-term survival in Her2-positive (HER2+) metastatic breast cancer (MBC)
    Murthy, Pooja
    Kidwell, Kelley M.
    Thomas, Dafydd G.
    Griggs, Jennifer J.
    Merajver, Sofia D.
    Schott, Anne F.
    Smerage, Jeffrey B.
    Van Poznak, Catherine H.
    Wicha, Max
    Hayes, Daniel F.
    Henry, N. Lynn
    CANCER RESEARCH, 2015, 75
  • [8] Herceptin® alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer:: Pivotal trials
    Baselga, J
    ONCOLOGY, 2001, 61 : 14 - 21
  • [9] Cardiac safety guidelines for the adjuvant use of trastuzumab (Herceptin®) in HER2-positive early breast cancer
    Ewer, M. S.
    Perez, E. A.
    Baselga, J.
    Bell, R.
    Brutsaert, D.
    Marty, M.
    Pienkowski, T.
    Suter, T. M.
    BREAST, 2007, 16 : S63 - S63
  • [10] Hypofunction of macrophage chemotaxis contributes to defective efficacy of herceptin in HER2-positive breast cancer patients
    Song, Yu
    Geng, Qiao-Chen
    An, Wen-Jing
    Zhang, Fu-Cheng
    Jiang, Ran
    Zhao, Rui-Sheng
    Deng, Zhi-Jian
    Li, Heng
    MOLECULAR & CELLULAR ONCOLOGY, 2024, 11 (01)
12345